Known throughout the world, Health Economics and Outcome Research is a peer-reviewed journal. This peer-reviewed journal covers a broad range of subjects. Since the journal accepts submissions in the forms of research articles, review articles, case studies, brief messages, and commentaries, authors are invited to do so. The subject of health economics and outcomes research (HEOR) is expanding and has gathered significant momentum in recent years. Although the relevance of studies determining a product's safety and effectiveness in the development and commercialization of medicines is well known. The potential for commercial success is a crucial factor when determining the expected value of a new patented medicine, though, due to the complexity of the mechanisms of reimbursement, regulation, and other factors that influence market uptake. The growing significance of what is frequently referred to as "market access" on the road to commercial success appears to support the case for investing in HEOR. Objectives Pharmaceutical/Biotechnology Companies The main objectives of pharmaceutical businesses are to create novel treatments, maximise earnings in a global market, and increase market share of their goods. Pharmaceutical firms either function in an oligopolistic market or have a monopoly if they are the best in their class. A global market supports the operations of pharmaceutical businesses. Models and evidence are produced during product development to measure a product's economic worth or to assess the longer-term outcomes of patients associated to the product's use. The HEOR strategy is often integrated with the overall product strategy. Commercial Payers/Pharmacy Benefit Managers The main objectives of pharmaceutical businesses are to create novel treatments, maximise earnings in a global market, and increase market share of their goods. Pharmaceutical firms either function in an oligopolistic market or have a monopoly if they are the best in their class. A global market supports the operations of pharmaceutical businesses. Models and evidence are produced during product development to measure a product's economic worth or to assess the longer-term outcomes of patients associated to the product's use. The HEOR strategy is often integrated with the overall product strategy. Two categories of research may be included in HEOR investments: (1) Economic and cost-related research; and (2) research involving the evaluation of health outcomes. Despite the fact that these factors are connected and occasionally employed together, a sizable portion of HEOR research scientists focus on either one or the other. The extent of investments a HEOR function might make while a product is being developed to prove its worth for reimbursement. Following is a list and quick description of the various categories of evidence: • Budget impact: Calculates the cost of a plan's decision to cover a medicine in a particular situation. Drug prices, treatment costs, cost of adverse events, and other expenditures that can be added to or subtracted by the usage of treatment are all possible inclusions in models. • Cost of illness: Measures the severity of the disease problem in a particular population at a certain time. Costs, quality of life, and/or length of life lost as a result of the existence of a particular disease are considered to be burdens and are therefore theoretically preventable with the employment of a therapy. • Cost-utility: Calculates the incremental costs, benefits, and implications of a new therapy in comparison to the accepted standard of care. Cost-utility is a specific example where benefits and consequences are assessed using QALYs. Incremental benefits are measured in the same units. • Disease incidence: In order to determine the size of the intended patient population, disease incidence/prevalence estimates the frequency of new cases of a disease that appear during a given time frame or the percentage of a population affected by a disease at a given moment. • Indirect treatment comparisons: Compares treatments that were not directly evaluated in headto-head studies by synthesizing data from clinical studies and adjusting for the different patient populations in each study to evaluate how treatments might fare against one another if they had been directly compared. • Patient health-related quality of life (HRQOL): examines an individual's health status, attitudes, values, and perceived levels of satisfaction with regard to certain health states or life in general. An individual's desire for a specific health state under uncertain circumstances is expressed quantitatively as utility. In order to increase the quality of the information, health economics must be taken into account while making healthcare decisions. It helps to enlighten and enhance decision-making by offering a structured and objective framework of thought. Whether or whether a formal economic review is carried out, considering alternative choices for achieving predetermined objectives and balancing resource and benefit considerations represents an effective way of thinking for decision-making. Authors are welcome to submit the manuscript at www.scholarscentral.org/submissions/health-economics-outcome-research-open-access.html Twitter: @OpenAccess_OMICS Whatsapp No: +44 7915 641605